StockData

Immunocore vs Iovance Biotherapeutics

IMCR and IOVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IMCR and IOVA compare

Iovance Biotherapeutics is the larger company, worth 2.4 times as much as Immunocore ($3.4B against $1.4B).

Iovance Biotherapeutics grew revenue faster over the last twelve months (34.5% versus 21.0% for Immunocore).

Immunocore keeps more of each dollar of sales as profit, with a net margin of −4.2% compared with −89.1% at Iovance Biotherapeutics.

Iovance Biotherapeutics scores higher on the StockData Score (9 against 7 for Immunocore), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIMCRIOVA
Size and price
Market cap$1.4B$3.4B
Share price$27.81$7.53
Change, 1 year−22.6%205%
Change, 5 years−23.6%−59.3%
Beta (5Y)0.191.45
Employees524975
StockData Score
Total score79 (better)
Valuation score1 (better)0
Growth score22
Performance score3 (better)1
Health score16 (better)
Dividend score00
Valuation
P/S3.3× (better)10.5×
P/B3.4× (better)4.6×
FCF yield−2.9% (better)−8.7%
Fair value$32.29$4.03
Margin of safety13.9% (better)−86.8%
Growth
Revenue growth (TTM)21.0%34.5% (better)
Profitability
Gross margin98.9% (better)48.4%
Operating margin−5.2% (better)−92.7%
Net margin−4.2% (better)−89.1%
FCF margin−9.6% (better)−91.2%
Return on equity−4.5% (better)−40.4%
Return on invested capital–−57.0%
Financial health
Debt / equity–0.00
Interest coverage−1.8×–
Current ratio4.47 (better)4.35
Altman Z-score1.406.70 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Dividend yield0.00%–
Years of dividend growth0–
Buyback yield–−8.6%
Shareholder yield0.00% (better)−8.6%
Ownership
Held by institutions102%63.3%
Held by insiders15.5%0.39%
Insider net buying, 12 months−$1.9M–
Short interest, % of float–14.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.